Engineering antibodies for clinical applications in cancer

Tumor Biology

Volumn 25, Issue 1-2, 2004, Pages 91-98

  Chester, Kerry ^a   Pedley, Barbara ^a   Tolner, Berend ^a   Violet, John ^a   Mayer, Astrid ^a   Sharma, Surinder ^a   Boxer, Geoff ^a   Green, Alan ^a   Nagl, Sylvia ^a   Begent, Richard ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Antibody directed enzyme prodrug therapy; Cancer; Clinical trials; Radioimmunotherapy; Single chain Fv

Indexed keywords

ANTIBODY CONJUGATE; CARBOXYPEPTIDASE G2; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 131; COMBRETASTATIN A4 PHOSPHATE; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE 131; MFE 23; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADVANCED CANCER; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY ENGINEERING; ANTIGEN SPECIFICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG UPTAKE; GENE CONSTRUCT; HODGKIN DISEASE; HUMAN; ISOTOPE LABELING; LEUKEMIA; LYMPHOMA; MOLECULAR CLONING; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 3042545775     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077727     Document Type: Review

References (36)

1. von Behring E, Kitasato S: 'The mechanism of immunity in animals to diphtheria and tetanus' (1890); in Brock T (ed): Milestones in Microbiology. London, Prentice-Hall International, 1961, pp 138-140.
2. Hericourt J, Richet C: 'Physologie pathologique' - de la serotherapie dans le traitement du cancer. C R Hebd Seanc Acad Sci 1895;121:567.
3. Currie GA: Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer. Br J Cancer 1972;26:141-153.
4. Mach JP, Chatal JF, Lumbroso JD, Buchegger F, Forni M, Ritschard J, Berche C, Douillard JY, Carrel S, Herlyn M: Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 1983;43:5593-5600.
5. Carter P: Improving the efficacy of antibodybased cancer therapies. Nat Rev Cancer 2001;1:118-129.
6. Glennie MJ, van de Winkel JG: Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003;8:503-510.
7. Hudson PJ, Souriau C: Engineered antibodies. Nat Med 2003;9:129-134.
8. Winter G, Milstein C: Man-made antibodies. Nature 1991;349:293-299.
9. Flynn AA, Pedley RB, Green AJ, Boxer GM, Boden R, Bhatia J, Morris R, Begent RH: Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumor. Int J Radiat Biol 2002;78:407-415.
10. Boxer G, Stuart-Smith S, Flynn A, Green A, Begent R: Radioimmunoluminography: A tool for relating tissue antigen concentration to clinical outcome. Br J Cancer 1999;80:922-926.
11. Begent RH, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, Keep PA, Adam T, Dale RG, Glaser MG: Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer 1989;60:406-412.
12. Lane DM, Eagle KF, Begent RH, Hope-Stone LD, Green AJ, Casey JL, Keep PA, Kelly AM, Ledermann JA, Glaser MG: Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: Phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer 1994;70:521-525.
13. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 2001;61:4716-4722.
14. Pedley RB, El Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, Hill SA, Stuart S, Motha R, Begent RH: Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 2002;54:1524-1531.
15. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF: A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988;58:700-703.
16. Bagshawe KD: Antibody-directed enzyme prodrug therapy for cancer: Its theoretical basis and application. Mol Med Today 1995;1:424-431.
17. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH: Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000;6:765-772.
18. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH: A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 2002;87:600-607.
19. Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H: Medical applications of single-chain antibodies. Int Rev Immunol 1993;10:195-217.
20. McCafferty J, Griffiths AD, Winter G, Chiswell DJ: Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990;348:552-554.
21. Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, Cochet O, Hawkins RE: Phage libraries for generation of clinically useful antibodies. Lancet 1994;343:455-456.
22. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-984.
23. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AA, Winslet MC, Dhillon AP, Hilson AJ, Begent RH: Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000;6:1711-1719.
24. Michael NP, Chester KA, Melton RG, Robson L, Nicholas W, Boden JA, Pedley RB, Begent RH, Sherwood RF, Minton NP: In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology 1996;2:47-57.
25. Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, Read DA, Boxer GM, Michael NP, Begent RH: Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer 2000;85:571-577.
26. Medzihradszky KF, Spencer DI, Sharma SK, Bhatia J, Pedley RB, Read DA, Begent RH, Chester KA: Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 2004;14:27-37.
27. Fraser IP, Koziel H, Ezekowitz RA: The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 1998;10:363-372.
28. Gordon S: Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002;111:927-930.
29. East L, Isacke CM: The mannose receptor family. Biochim Biophys Acta 2002;1572:364-386.
30. Francis RJ, Mather SJ, Chester KA, Sharma SK, Bhatia J, Boden R, Waibel R, Green AJ, Begent RHJ: Technetium-99m carbonyl radiolabelling of his-tagged glycosylated MFE-23:: CPG2 fusion protein (MFECP1) for quantitation of biodistribution of antibody-enzyme in ADEPT. Eur J Nucl Med, in press.
31. Casey JL, Keep PA, Chester KA, Robson L, Hawkins RE, Begent RH: Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol Methods 1995;179:105-116.
32. Nagl SB: Computational function assignment for potential drug targets: From single genes to cellular systems. Curr Drug Targets 2002;3:387-399.
33. Boehm MK, Corper AL, Wan T, Sohi MK, Sutton BJ, Thornton JD, Keep PA, Chester KA, Begent RH, Perkins SJ: Crystal structure of the anti- (carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 2000;346:519-528.
34. Boehm MK, Perkins SJ: Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody molecule MFE23. FEBS Lett 2000;475:11-16.
35. Lee YC, Boehm MK, Chester KA, Begent RH, Perkins SJ: Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J Mol Biol 2002;320:107-127.
36. Spencer DI, Robson L, Purdy D, Whitelegg NR, Michael NP, Bhatia J, Sharma SK, Rees AR, Minton NP, Begent RH, Chester KA: A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics 2002;2:271-279.